Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666129 · ClinicalTrials.gov registry record · Phase 1
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04666129 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 48 participants.
The verdict
NCT04666129, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).
Interventions
- DRUG Apalutamide
- DRUG Relugolix
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04666129
The ClinicalTrials.gov registry entry for NCT04666129 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Apalutamide is the first listed.
NCT04666129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04666129 about?
NCT04666129 is a clinical study titled "Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer". This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic c...
What is the current status of trial NCT04666129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-02-18. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT04666129?
The interventions under investigation include: Apalutamide (DRUG), Relugolix (DRUG), Prednisone (DRUG), Abiraterone (DRUG), Methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT04666129?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.